|
Groups
|
Day after challenge
|
P value
|
|---|
|
Day after the end of medication
|
Last day (before death)
|
|---|
|
Untreated
|
–
|
11,804,800
|
P < 0.001
|
|
PYR
|
1,870,800
|
916,000
|
P < 0.001
|
|
P value
|
P < 0.009
| | |
|
Untreated
|
-
|
11,804,800
|
P < 0.001
|
|
FLU 20 mg + PYR
|
1,746,000
|
1,052,000
|
P < 0.001
|
|
P value
|
P < 0.009
| | |
|
Untreated
|
–
|
11,804,800
|
P < 0.001
|
|
FLU 40 mg + PYR
|
1,592,400
|
1,556,000
|
P < 0.001
|
|
P value
|
P < 0.009
| | |
|
Untreated
|
–
|
11,804,800
|
P < 0.001
|
|
FLU 80 mg + PYR
|
2,466,000
|
2,004,400
|
P < 0.001
|
|
P value
|
P < 0.009
| | |
- Results are the mean ± standard deviation of the quantity of DNA obtained from three different treatment groups. Kruskal–Wallis test compared the groups at the significance level of 0.05. Mann–Whitney U test was used for multiple comparisons between groups and different days. Bonferroni correction was used to change the significance level to 0.01 and 0.025. Parasite load of Toxoplasma tachyzoites indicated the statistically significant difference among t the two groups and different days
